UTHR (STOCKS)
United Therapeutics Corp
$475.850000
+2.650000 (+0.56%)
Prev close: $473.200000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Martine A. Rothblatt
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $20,487.62M
- Employees
- 1,305
- P/E (TTM)
- 18.03
- P/B (TTM)
- 3.10
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $3.08B |
| Benefits Costs and Expenses | $1.46B |
| Cost Of Revenue | $339.10M |
| Costs And Expenses | $1.63B |
| Gross Profit | $2.74B |
| Nonoperating Income/Loss | $168.90M |
| Operating Expenses | $1.29B |
| Selling, General, and Administrative Expenses | $770.30M |
| Research and Development | $520.30M |
| Operating Income/Loss | $1.45B |
| Income/Loss From Continuing Operations After Tax | $1.24B |
| Income/Loss From Continuing Operations Before Tax | $1.62B |
| Income Tax Expense/Benefit | $374.90M |
| Net Income/Loss | $1.24B |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $1.24B |
| Net Income/Loss Available To Common Stockholders, Basic | $1.24B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $27.68 |
| Diluted Earnings Per Share | $25.62 |
| Basic Average Shares | 89,500,000 |
| Diluted Average Shares | 96,900,000 |
| Assets | $7.91B |
| Current Assets | $3.83B |
| Inventory | $169.20M |
| Other Current Assets | $3.66B |
| Noncurrent Assets | $4.08B |
| Fixed Assets | $1.36B |
| Other Non-current Assets | $2.72B |
| Liabilities | $734.40M |
| Current Liabilities | $527.10M |
| Noncurrent Liabilities | $207.30M |
| Equity | $7.17B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $7.17B |
| Liabilities And Equity | $7.91B |
| Net Cash Flow From Operating Activities | $1.37B |
| Net Cash Flow From Operating Activities, Continuing | $1.37B |
| Net Cash Flow From Investing Activities | -$702.70M |
| Net Cash Flow From Investing Activities, Continuing | -$702.70M |
| Net Cash Flow From Financing Activities | -$431.20M |
| Net Cash Flow From Financing Activities, Continuing | -$431.20M |
| Net Cash Flow | $237.40M |
| Net Cash Flow, Continuing | $237.40M |
| Comprehensive Income/Loss | $1.26B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $1.26B |
| Other Comprehensive Income/Loss | $1.26B |
| Other Comprehensive Income/Loss Attributable To Parent | $14.90M |